Natural killer (NK) cell immunotherapies have generally demonstrated a more favorable safety profile in clinical trials compared to traditional autologous CAR-T therapies. They typically show significantly lower rates of severe cytokine release syndrome (CRS) and neurotoxicity, although clinical evaluations regarding long-term safety and infection risks remain active.